Valeant Pharmaceuticals Launches Bedoyecta(TM) in the United States

Share Article

Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has launched Bedoyecta(TM), the leading nutritional supplement in Mexico, in the United States through Hispanic independent grocers and major retailers serving ethnic communities. Bedoyecta will be available in capsule and pediatric tablet form and will initially launch in Los Angeles and Houston in September 2007 with a national rollout by the end of the year.

We are committed to providing the U.S. consumer with quality brands and it is important that we recognize the growth of the U.S. Hispanic population and the preferences of the Hispanic consumer.

    "We are pleased to offer our Bedoyecta products to the Hispanic communities in the United States who have long known the brand in Mexico," said Wesley P. Wheeler, president, North America and Research and Development. "We are committed to providing the U.S. consumer with quality brands and it is important that we recognize the growth of the U.S. Hispanic population and the preferences of the Hispanic consumer."

Bedoyecta has been a trusted name in Mexico and Latin America for more than 20 years. Bedoyecta is the leading vitamin brand and the third largest over-the-counter product in Mexico. According to the National Center for Health Statistics, approximately 40 percent of Hispanics in Mexico use vitamin supplements. With the continued expansion of the Hispanic population in the United States, a majority of which trace their roots to Mexico, Bedoyecta promises to be an appealing and profitable product for U.S. retailers who cater to Hispanic consumers.

Valeant has assigned Houston-based Midway Importing Inc. as the distributor for Bedoyecta. Midway Importing currently services most Hispanic independent and chain grocers, pharmacy retail chains, and mass merchandisers that service the Hispanic market.

About Valeant:

Valeant Pharmaceuticals International (NYSE:VRX) is a global specialty pharmaceutical company that develops, manufactures and markets products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at http://www.valeant.com.

Bedoyecta is a trademark of Valeant Pharmaceuticals International or its related companies. For information on Bedoyecta visit http://www.BedoyectaUS.com or http://www.BedoyectaMX.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeff Misakian
Valeant Pharmaceuticals
949-461-6184
Email >